Grace Therapeutics, Inc. (GRCE) financials · $35.0M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Grace Therapeutics, Inc. (GRCE) $35.0M cap.
| Line | FY2026 | FY2025 | Pro (2 older periods with Lician Pro) |
|---|---|---|---|
| Operating Income | −$11.08M | −$16.68M | |
| Net Income | −$7.79M | −$9.57M | |
| EPS (Diluted) | −$0.47 | −$0.79 | |
| Unlock 5 years of statements: Lician Pro $149/yr | |||
| Line | FY2026 | FY2025 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Total Assets | $66.65M | $71.99M | |
| Current Assets | $17.38M | $22.71M | |
| Cash & Equivalents | $16.98M | $22.13M | |
| PP&E | $8.00K | $15.00K | |
| Total Liabilities | $2.76M | $5.38M | |
| Current Liabilities | $2.15M | $1.93M | |
| Shareholders' Equity | $63.90M | $66.61M | |
| Retained Earnings | −$228.48M | −$220.69M |
| Line | FY2026 | FY2025 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Operating Cash Flow | −$8.87M | −$14.90M | |
| Investing Cash Flow | — | — | |
| Financing Cash Flow | $3.71M | $14.03M | |
| Net Change in Cash | −$5.16M | −$872.00K |
Source: Company filings with the SEC (EDGAR) · Latest period FY2026
FAQ
What is GRCE P/E and revenue?
Grace Therapeutics, Inc. (GRCE) $35.0M cap.
What is GRCE revenue?
GRCE income-statement cache has no revenue figure yet.
Is GRCE profitable?
Grace Therapeutics, Inc. last cached net income is -$7.79M (FY2026).
What are GRCE total assets?
Grace Therapeutics, Inc. last cached total assets are $66.7M (FY2026).
What is GRCE free cash flow?
No cached cash-flow row for GRCE yet.
Not investment advice. Figures as reported in company filings, not a live feed.